↓ Skip to main content

Targeting of erbB3 receptor to overcome resistance in cancer treatment

Overview of attention for article published in Molecular Cancer, May 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)

Mentioned by

news
1 news outlet
twitter
1 tweeter
patent
1 patent

Citations

dimensions_citation
130 Dimensions

Readers on

mendeley
157 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Targeting of erbB3 receptor to overcome resistance in cancer treatment
Published in
Molecular Cancer, May 2014
DOI 10.1186/1476-4598-13-105
Pubmed ID
Authors

Jian Ma, Hui Lyu, Jingcao Huang, Bolin Liu

Abstract

The erbB receptors, including the epidermal growth factor receptor (EGFR), erbB2 (also known as HER2/neu), erbB3 (or HER3), and erbB4 (or HER4), are often aberrantly activated in a wide variety of human cancers. They are excellent targets for selective anti-cancer therapies because of their transmembrane location and pro-oncogenic activity. While several therapeutic agents against erbB2 and/or EGFR have been used in the treatment of human cancers with efficacy, there has been relatively less emphasis on erbB3 as a molecular target. Elevated expression of erbB3 is frequently observed in various malignancies, where it promotes tumor progression via interactions with other receptor tyrosine kinases (RTKs) due to its lack of or weak intrinsic kinase activity. Studies on the underlying mechanisms implicate erbB3 as a major cause of treatment failure in cancer therapy, mainly through activation of the PI-3 K/Akt, MEK/MAPK, and Jak/Stat signaling pathways as well as Src kinase. It is believed that inhibition of erbB3 signaling may be required to overcome therapeutic resistance and effectively treat cancers. To date, no erbB3-targeted therapy has been approved for cancer treatment. Targeting of erbB3 receptor with a monoclonal antibody (Ab) is the only strategy currently under preclinical study and clinical evaluation. In this review, we focus on the role of erbB3-initiated signaling in the development of cancer drug resistance and discuss the latest advances in identifying therapeutic strategies inactivating erbB3 to overcome the resistance and enhance efficacy of cancer therapeutics.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 157 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Pakistan 1 <1%
Canada 1 <1%
Belgium 1 <1%
Denmark 1 <1%
United States 1 <1%
Unknown 152 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 50 32%
Student > Ph. D. Student 27 17%
Student > Master 16 10%
Other 11 7%
Student > Bachelor 7 4%
Other 21 13%
Unknown 25 16%
Readers by discipline Count As %
Agricultural and Biological Sciences 44 28%
Biochemistry, Genetics and Molecular Biology 38 24%
Medicine and Dentistry 26 17%
Pharmacology, Toxicology and Pharmaceutical Science 10 6%
Engineering 2 1%
Other 8 5%
Unknown 29 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 December 2020.
All research outputs
#2,010,243
of 19,814,211 outputs
Outputs from Molecular Cancer
#73
of 1,486 outputs
Outputs of similar age
#22,745
of 201,995 outputs
Outputs of similar age from Molecular Cancer
#1
of 1 outputs
Altmetric has tracked 19,814,211 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,486 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 201,995 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them